Regeneron, an expensive monoclonal antibody cocktail, has been approved by the World Health Organization for COVID-19 patients at high risk of hospitalization. Jamie Mauracher explains how the treatment works, why it’s rarely used in Canada, and how some COVID-19 survivors are reacting to the news.
- U.S. limits use of Regeneron, Eli Lilly COVID-19 antibody treatments amid Omicron spread
- Standard drugs used to fight COVID-19 may not work against Omicron: U.S. doctors
- AstraZeneca COVID-19 drug prevents severe disease if given early, company says